The initiative aims to balance pharmaceutical safety with the facilitation of trade and the smooth movement of shipments ...

The investment bank said many companies faced thesis-changing Phase 3 readouts this year, with outcomes that could materially reshape valuations regardless of the broader macro backdrop. But UBS also ...

While 2025 was the year of disruption for Trump’s pharma policies, we expect 2026 to be the year of truth: will the US ...

Smaller pharmaceutical companies in Europe are now bracing to be the focus of the Trump administration’s lobbying after 16 of ...

Let's consider three of them: Eli Lilly ( LLY +0.52%), AbbVie ( ABBV 0.31%), and Intuitive Surgical ( ISRG 1.15%). Here's why ...

Ahead of her presentation at JP Morgan, Pharmaceutical Technology spoke with Dr. Jennifer Levin Carter, MD, founder and CEO ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best debt-free penny stocks to buy right now. On December 17, ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s ...

President Donald Trump announced via video his plan to lower healthcare costs, focusing on the deals he previously made with ...

In our final batch of Changing Faces columns for 2025, we’re detailing a flurry of senior leadership appointments in recent ...